

**Table S1.** Primers used for reverse transcription-quantitative polymerase chain reaction.

<b>Gene</b>	<b>Forward (5' to 3')</b>	<b>Reverse (5' to 3')</b>
ENAH	GTGGCTCAACTGGATTCAGCA	AGGAATGGCACAGTTTATCACGA
SEPT9	CCACTGCTGCCTCTACTTCATC	GGTCCTCCGAGTCCTCATCAA
EGF	TTCAAGCCTTGTCTTTCGT	TTCAAATCAGCAAAAGCATAAA
MMP-9	AAGGGCGTCGTGGTTCCAA	CGGTCGTCCGGTGTCTAGTT
CXCL8	GCTCTCTTGGCAGCCTTCT	TGGTCCACTCTCAATCACTCTCA
$\beta$ -actin	TGGCACCCAGCACAATGAA	CTAAGTCATAGTCCGCCTAGAAGCA
GAPDH	GACCTGACCTGCCGTCTA	AGGAGTGGGTGTCTCGCTGT

ENAH, enabled homolog; SEPT9, septin 9; EGF, epidermal growth factor, MMP-9, matrix metalloproteinase-9; CXCL8, C-X-C motif chemokine ligand 8; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

**Table SII.** Comparison of the clinical characteristics between the two batches of patients with breast cancer.

Items	First batch (n=31)	Second batch (n=16)	P-value
Age (years), mean±SD	55.1±12.3	53.5±10.0	0.656
Menopause, n (%)			1.000
No	24 (77.4)	12 (75.0)	
Yes	7 (22.6)	4 (25.0)	
Histological type, n (%)			0.205
Ductal carcinoma <i>in situ</i>	3 (9.7)	0 (0.0)	
Invasive ductal carcinoma	23 (74.2)	11 (68.8)	
Invasive lobular carcinoma	1 (3.2)	3 (18.8)	
Others	4 (12.9)	2 (12.5)	
Molecular subtypes, n (%)			0.720
Triple-negative	2 (6.5)	0 (0.0)	
Luminal A	5 (16.1)	2 (12.5)	
HER2-negative luminal B	6 (19.4)	4 (25.0)	
HER2-positive luminal B	12 (38.7)	5 (31.3)	
HER2-enriched	6 (19.4)	5 (31.3)	
Hormone receptor status, n (%)			0.739
ER negative and PR negative	8 (25.8)	5 (31.3)	
ER positive and/or PR positive	23 (74.2)	11 (68.8)	
HER2, n (%)			0.769
Negative	13 (41.9)	6 (37.5)	
Positive	18 (58.1)	10 (62.5)	
Ki-67, n (%)			0.739
<30%	23 (74.2)	11 (68.8)	
≥30%	8 (25.8)	5 (31.3)	
TNM stage, n (%)			0.389
0	4 (12.9)	0 (0.0)	
I	10 (32.3)	3 (18.8)	
II	13 (41.9)	9 (56.3)	
III	3 (9.7)	3 (18.8)	
IV	1 (3.2)	1 (6.3)	
Surgical type, n (%)	31 (100.0)	16 (100.0)	-
Modified radical mastectomy	11 (35.5)	13 (81.3)	0.003
Sentinel lymph node biopsy	16 (51.6)	2 (12.5)	0.009
Radical mastectomy	14 (45.2)	1 (6.3)	0.007
Breast-conserving surgery	3 (9.7)	2 (12.5)	1.000

Neoadjuvant therapy, n (%)	3 (9.7)	6 (37.5)	0.045
Adjuvant therapy, n (%)	28 (90.3)	16 (100.0)	0.541

---

SD, standard deviation; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor; TNM, tumor-node-metastasis.